Urolithin A Encyclopedia — Scientific Background

What Is Urolithin A?

Urolithin A (CAS 1143-70-0), also known as 3,8-dihydroxybenzo[c]chromen-6-one or Uro-A, is a naturally occurring gut microbiota-derived metabolite of ellagitannins and ellagic acid. It is chemically characterized by the molecular formula C₁₃H₈O₄ and a molecular weight of 228.20 g/mol. Urolithin A is the primary effector responsible for the health benefits conferred by ellagitannin/ellagic acid-rich foods such as pomegranates, walnuts, and berries.

The Urolithin Metabotypes

A significant challenge with urolithin A is its dependence on gut microbiota composition for conversion from dietary precursors. The ability to produce urolithin A varies significantly among individuals, with three distinct metabotypes identified: Urolithin Metabotype A (produces urolithin A), Urolithin Metabotype B (produces urolithin B and isourolithin A), and Urolithin Metabotype 0 (non-producers). Approximately 10% of individuals are classified as urolithin nonproducers, independent of age. Liposomal urolithin a bypasses this dependency entirely, delivering the active compound directly without requiring gut microbiota conversion.

Mechanisms of Action

Mitophagy Activation — The PINK1/Parkin Pathway

Urolithin A‘s primary and most distinctive mechanism of action is the induction of mitophagy—the selective autophagic degradation of damaged and dysfunctional mitochondria. The best-characterized pathway is the PINK1-Parkin cascade. In functional mitochondria, PINK1 is imported into the inner mitochondrial membrane and subsequently degraded. However, upon depolarization, PINK1 accumulates on the outer membrane, recruiting and activating Parkin. Parkin then ubiquitinates mitochondrial proteins, tagging the damaged organelle for autophagic removal.

Research demonstrates that UA induces mitophagy in various mammalian cells. UA significantly increased ATP content and mitochondrial DNA integrity, and decreased the expression of senescence-associated p53 and p21, while increasing the expression of mitophagy-related proteins. Treatment with UA restored autophagic flux and triggered PINK1/Parkin-dependent mitophagy.

Mitochondrial Biogenesis

In addition to removing damaged mitochondria, UA promotes the formation of new, healthy mitochondria. Clinical trial analysis revealed augmented mitochondrial biogenesis in CD8⁺ cells following UA supplementation. In preclinical models, UA increased proteins associated with mitochondrial fusion, antioxidant defense, and biogenesis.

Anti-Inflammatory Effects

A systematic review of five studies including 250 healthy individuals demonstrated that UA (10–1,000 mg/day) for 28 days to 4 months showed a dose-dependent anti-inflammatory effect and upregulated some mitochondrial genes, markers of autophagy, and fatty acid oxidation.

Immune Function Modulation

Urolithin A has demonstrated the ability to counteract age-related immune decline. In a randomized, double-blind, placebo-controlled trial, UA expanded peripheral naive-like, less terminally exhausted CD8⁺ cells while increasing CD8⁺ fatty acid oxidation capacity. UA treatment also increased peripheral NK cells and nonclassical monocytes, improved activation-elicited TNF secretion in T cells, and enhanced bacterial uptake by monocytes.

Metabolic Health Support

Preclinical evidence indicates that UA can restore hepatic antioxidant capacity and reduce lipid accumulation. Mechanistically, UA activates the AMPK pathway to promote hepatic lipophagy and enhances fatty acid oxidation, thereby lowering triglyceride buildup. In a high-fat diet-induced mouse model of non-alcoholic fatty liver disease, gum arabic-coated UA liposomes effectively alleviated hepatic steatosis, inflammation, and oxidative stress through activation of the AMPK/Nrf2 signaling pathway.

The Bioavailability Challenge

Despite its promising biological activities, urolithin A presents significant formulation challenges. The compound has low water solubility and poor oral bioavailability, and its clinical translation is hampered by significant inter-individual variability in gut microbiota composition and intestinal absorption, leading to inconsistent bioconversion and bioavailability. Pharmacokinetic studies indicate low plasma exposure under standard administration, and approximately 10% of individuals are urolithin nonproducers.

liposomal encapsulation addresses these limitations through a phospholipid bilayer that protects UroA during digestive transit, enhances intestinal absorption through lipid-mediated pathways, and bypasses the need for gut microbiota conversion entirely.

Liposomal Urolithin A

Liposomal encapsulation of urolithin A provides a fundamentally different delivery mechanism from conventional forms. The phospholipid bilayer surrounds the UroA molecule, forming a protective shell that enhances absorption and facilitates direct delivery to target tissues. This delivery system:

• Bypasses gut microbiota dependency for activation

• Improves relative oral bioavailability by 3.09-fold compared to free UroA

• Enhances encapsulation efficiency, stability, and bioaccessibility

• Provides targeted delivery to mitochondria in skeletal muscle, immune cells, and brain tissue

Gum arabic-coated urolithin A liposomes (UA-LPs-GA) significantly enhanced the encapsulation efficiency, stability, and bioaccessibility of UroA. Liposomes coated with gum arabic showed the best encapsulation efficiency, bioaccessibility, storage and thermal stability, with bioaccessibility reaching 1.67 times that of uncoated UroA liposomes. pH-driven liposomal encapsulation demonstrated a 1.91-fold increase in absorption efficiency compared to conventional thin-film methods.

Clinical Evidence

Muscle Strength and Endurance

A systematic review assessing the potential geroprotective effect of UA in humans evaluated five studies including 250 healthy individuals. UA (10–1,000 mg/day) for a duration ranging from 28 days to 4 months increased muscle strength and endurance. However, it had no effect on anthropometrics, cardiovascular outcomes, and physical function. Unrelated adverse events were mild or moderate.

Immune Function and Aging

A randomized, double-blind, placebo-controlled trial in 50 healthy middle-aged adults evaluated oral UA (1,000 mg/day) or placebo for 4 weeks. UA expanded peripheral naive-like, less terminally exhausted CD8⁺ cells (treatment difference 0.50 percentage points; 95% CI = 0.16 to 0.83; P = 0.0437) while also increasing CD8⁺ fatty acid oxidation capacity (treatment difference = 14.72 percentage points; 95% CI = 6.46 to 22.99; P = 0.0061). Secondary outcomes revealed augmented mitochondrial biogenesis in CD8⁺ cells, increased peripheral NK cells and nonclassical monocytes, and improved activation-elicited TNF secretion in T cells and bacterial uptake by monocytes. These findings indicate that short-term UA supplementation modulates human immune cell composition and function, supporting its potential to counteract age-related immune decline and inflammaging.

Cognitive Function — Preclinical Evidence

In aged mouse models, UA administration for 8 weeks increased ATP production, boosted proteins associated with mitochondrial fusion, antioxidant defense, and biogenesis, and reduced phosphorylated tau. In accelerated aging SAMP8 mice, UA produced stronger effects: ATP rose sharply, mitochondrial stress and aberrant proteins decreased, and cognitive performance improved. These findings highlight UA effects as a preventive therapeutic agent, suggesting early mitophagy activation is critical to mitigate brain aging and neurodegeneration.

Non-Alcoholic Fatty Liver Disease

In a high-fat diet-induced mouse model of NAFLD, UA-LPs-GA administration effectively alleviated key pathological features, including hepatic steatosis, inflammation, and oxidative stress, with superior efficacy to free UroA. Mechanistic studies revealed that the hepatoprotective effects were mediated through activation of the AMPK/Nrf2 signaling pathway. Additionally, UA-LPs-GA positively modulated the intestinal flora, enriching beneficial bacteria and suppressing harmful taxa.

Safety and Regulatory

Urolithin A is generally well tolerated. In a systematic review of five studies including 250 healthy individuals, unrelated adverse events were mild or moderate. A randomized, placebo-controlled trial demonstrated that the mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Side effects are generally absent or mild, and include gastrointestinal upset and diarrhea.

Continuous intake of Urolithin A at 10 mg maintained a certain blood level and was expected to improve vascular endothelial function, and it was confirmed safe to take for 12 weeks. Urolithin A has been safe in short clinical trials in middle-aged and older adults, but long-term safety has not been established.

Urolithin A is commercialized as a dietary supplement ingredient under the brand name Mitopure. It is classified as a postbiotic compound and is available in the United States, Europe, and other regions. Testing protocols must adhere to international standards including USP, European Pharmacopoeia, and FAO/WHO Codex Alimentarius. Formulators should verify local regulatory requirements prior to market entry.

This product is intended for research, nutraceutical, and functional food applications. Not intended to diagnose, treat, cure, or prevent any disease.

629$/KG

459$/KG